These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36187072)

  • 1. Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
    Welsh N
    Ups J Med Sci; 2022; 127():. PubMed ID: 36187072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?
    Welsh N
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1743-50. PubMed ID: 22998750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
    Druker BJ
    Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice.
    Han MS; Chung KW; Cheon HG; Rhee SD; Yoon CH; Lee MK; Kim KW; Lee MS
    Diabetes; 2009 Feb; 58(2):329-36. PubMed ID: 19171749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STI571 (Gleevec) as a paradigm for cancer therapy.
    Druker BJ
    Trends Mol Med; 2002; 8(4 Suppl):S14-8. PubMed ID: 11927282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
    Kirschner KM; Baltensperger K
    Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.
    Gur S; Kadowitz PJ; Hellstrom WJ
    J Sex Med; 2010 Oct; 7(10):3341-50. PubMed ID: 20584116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
    Nadal E; Olavarria E
    Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
    Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
    Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
    Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
    Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
    PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning.
    Hägerkvist R; Sandler S; Mokhtari D; Welsh N
    FASEB J; 2007 Feb; 21(2):618-28. PubMed ID: 17135364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
    Louvet C; Szot GL; Lang J; Lee MR; Martinier N; Bollag G; Zhu S; Weiss A; Bluestone JA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18895-900. PubMed ID: 19015530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Sawyers CL
    Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.